Caesarean Scar Pregnancy: Single Dose of Intrasac Ultrasound-Guided Methotrexate Injection Seems to be a Safe Option for Treatment.
cesarean scar pregnancy
ectopic pregnancy
gynecology
methotrexate
transvaginal ultrasound
Journal
Ultrasound international open
ISSN: 2509-596X
Titre abrégé: Ultrasound Int Open
Pays: Germany
ID NLM: 101674542
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
received:
04
10
2022
accepted:
15
03
2023
medline:
20
9
2023
pubmed:
20
9
2023
entrez:
20
9
2023
Statut:
epublish
Résumé
The purpose of the study was to assess the efficacy of local ultrasound-guided methotrexate injection in patients with caesarean section scar pregnancy, to chart the course of beta-human chorionic gonadotropin levels (HCG) after treatment, and to see if HCG levels are correlated with clinical presentation. Between May 2018 and January 2021, data were collected retrospectively from the Early Pregnancy Unit of a tertiary hospital. Our clinic assessed 20 patients; one disputed terminating the pregnancy and was not included in the research. The remaining 19 patients, with a median age of 34 years, received intragestational sac methotrexate injection under ultrasound guidance. 7w3d was the median gestational age. These women had one to four previous caesarean sections, with a mean of 1.60±9. Patients with caesarean scar pregnancy most typically presented with spotting (42.1%), whereas 26.3% were asymptomatic. Except in cases of pain, the symptomatic women's HCG levels were lower than in the non-symptomatic women. The level of HCG in patients with pain was approximately double that of non-pain patients (p=0.2557). In our series, intragestational sac methotrexate injection was effective in 17/19 women, or 89.5% (95%CI: 75.7-100%). HCG levels were undetectable in 97.6±30 days on average (minimum: 42 days, maximum: 147 days). Caesarean scar pregnancy is a rare possibly fatal condition with no consensus on the optimal treatment. An experienced Early Pregnancy Unit member performing local methotrexate injections under ultrasound guidance is a feasible and successful strategy in clinically stable patients.
Identifiants
pubmed: 37727679
doi: 10.1055/a-2137-8318
pii: uio0257
pmc: PMC10506866
doi:
Types de publication
Journal Article
Langues
eng
Pagination
E18-E25Informations de copyright
The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Déclaration de conflit d'intérêts
Conflict of Interest The authors declare that they have no conflict of interest.
Références
Ultrasound Obstet Gynecol. 2014 Apr;43(4):383-95
pubmed: 24357257
Australas J Ultrasound Med. 2015 Nov;18(4):150-156
pubmed: 28191259
Aust N Z J Obstet Gynaecol. 2015 Feb;55(1):64-9
pubmed: 25350856
Fertil Steril. 1997 Feb;67(2):398-400
pubmed: 9022622
Am J Perinatol. 2010 Feb;27(2):111-20
pubmed: 19504427
Hum Reprod. 2004 Feb;19(2):278-84
pubmed: 14747167
Am J Obstet Gynecol. 2016 Aug;215(2):225.e1-7
pubmed: 26899908
J Obstet Gynaecol Res. 2013 Jun;39(6):1153-8
pubmed: 23718134
Ultrasound Obstet Gynecol. 2003 Mar;21(3):220-7
pubmed: 12666214
S Afr Med J. 1978 Jan 28;53(4):142-3
pubmed: 653492
Obstet Gynecol. 1991 Mar;77(3):365-9
pubmed: 1992400
J Ultrasound Med. 2001 Oct;20(10):1105-15
pubmed: 11587017
BJOG. 2018 Dec;125(13):1663-1670
pubmed: 29697890
Ultrasound Obstet Gynecol. 2017 Jul;50(1):100-104
pubmed: 27420402
BJOG. 2007 Mar;114(3):253-63
pubmed: 17313383
J Ultrasound Med. 2012 Sep;31(9):1449-56
pubmed: 22922626
J Obstet Gynaecol Res. 2020 Feb;46(2):272-278
pubmed: 31943529
Acta Obstet Gynecol Scand. 2010 Dec;89(12):1592-4
pubmed: 20726832
Front Med (Lausanne). 2020 Nov 03;7:564764
pubmed: 33224958
Ultrasound Obstet Gynecol. 2004 Mar;23(3):247-53
pubmed: 15027012
Zhonghua Yi Xue Za Zhi. 2011 Dec 6;91(45):3186-9
pubmed: 22333100